Pharma Leaders Say AI Cannot Cure Disease Alone
Drugmaker executives push back on tech leaders' claims that artificial intelligence will soon eliminate most human disease.
Updated on Nov. 4, 2026 in Biotech
Live Poll
Do you trust AI companies to deliver real medical cures in the coming years?
Pharmaceutical executives said AI cannot cure disease on its own, even as Anthropic and OpenAI buy biotech companies and AstraZeneca announces an AI drug-developer collaboration. No drug designed by AI has yet won Food and Drug Administration clearance.
Why it matters
The disagreement highlights a gap between tech leaders' timelines for curing disease and the biological complexity drugmakers face in practice. For readers, it signals that AI's role in medicine is currently one of assisting discovery rather than replacing the lengthy research and testing process.
Vertex's experience with roughly 50 AI companies analyzing 10,000 compounds produced no working drug, and about a quarter of mid-to-late stage drug failures stem from off-target safety problems. Current AI models still struggle to predict these unintended effects in the body.
The players
Pascal Soriot
Soriot is the chief executive of AstraZeneca, a global pharmaceutical company, and has emphasized the biological complexity that AI tools must navigate.
Dario Amodei
Amodei is the chief executive of Anthropic, the artificial intelligence company, and has publicly predicted AI could help cure most human disease within a decade.
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company that tested roughly 50 AI firms on a 10,000-compound data set without producing a working drug.
OpenAI
OpenAI is an artificial intelligence research company that bought an AI drug-discovery biotech in October as it expands into life sciences.
Insitro
Insitro is an AI drug-discovery company that signed a collaboration with AstraZeneca targeting complex liver and heart diseases.
The details
AstraZeneca CEO Pascal Soriot said disease and biology are complicated, while Anthropic CEO Dario Amodei posted on X in September that curing most human disease in five to 10 years may be possible. AstraZeneca also announced a collaboration with Insitro to discover treatments for complex liver and heart diseases, paying $40 million upfront.
Timeline
September: Amodei posted that curing most human disease in five to 10 years may be possible.
October: OpenAI bought an AI drug-discovery biotech.
Tuesday: The Wall Street Journal published a report on drugmaker executives' comments.
Big Picture
AstraZeneca's Insitro deal, with its $1.46 billion in potential milestone payments, extends a wave of pharma-AI partnerships that has not yet produced a single FDA-cleared AI-designed drug. The current moment marks a test of whether these large deals can translate into approved medicines.
For patients, AI-assisted drug discovery may eventually shorten research timelines, but no AI-designed drug is yet approved, so treatments remain on conventional development schedules. Readers should expect claims of rapid cures to be tested against clinical trial results before they translate to available medicines.
The takeaway
AI is currently proving most useful as a tool that helps researchers choose targets and identify suitable patients, not as a shortcut past clinical testing. Claims of imminent cures should be weighed against the absence of any FDA-cleared AI-designed drug so far.
Further reading
Explore more on Biotech to see how AI is being applied to drug discovery.
Source note: This article includes information reported by Benzinga.
Live Poll
Do you trust AI companies to deliver real medical cures in the coming years?
